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ABSTRACT
Published CRRT drug dosing algorithms and other dos-
ing guidelines appear to result in underdosed antibiotics,
leading to failure to attain pharmacodynamic targets.
High mortality rates persist with inadequate antibiotic
therapy as the most important risk factor for death. Rea-
sons for unintended antibiotic underdosing in patients
receiving CRRT are many. Underdosing may result from
lack of the recognition that better hepatic function in
AKI patients yields higher nonrenal antibiotic clearance
compared to ESRD patients. Other factors include the
variability in body size and fluid composition of patients,
the serious consequence of delayed achievement of antibi-
otic pharmacodynamic targets in septic patients, potential
subtherapeutic antibiotic concentrations at the infection
site, and the influence of RRT intensity on antibiotic con-
centrations. Too often, clinicians weigh the benefits of
overcautious antibiotic dosing to avoid antibiotic toxicity
too heavily against the benefits of rapid attainment of
therapeutic antibiotic concentrations in critically ill
patients receiving CRRT. We urge clinicians to prescribe
antibiotics aggressively for these vulnerable patients.
“Without reflection, we go blindly on our way,
creating more unintended consequences, and fail-
ing to achieve anything useful.”
Margaret J. Wheatley
Finding Our Way: Leadership For an Uncertain
Time (2005) p. 262
Berrett-Koehler Publishers, Inc.
Continuous renal replacement therapy (CRRT)
has been universally accepted as a preferred treat-
ment for acute kidney injury (AKI) and fluid over-
load since first being described in 1977 (1). CRRT
has been studied from so many angles, (machine
design, therapy delivery, anticoagulation, vascular
access, economics, clinician education, etc.) and as a
result, its usage has become routine. In general, we
have done a good job of designing an effective sys-
tem for controlling azotemia, balancing electrolytes,
and removing fluid. In treating these critically ill
patients with very high mortality rates with CRRT
and other RRTs employed in the ICU, clinicians
are often quite judicious when it comes to antibiotic
dosing, and with good reason. Most antibiotics are
cleared by the kidney, and dosage reduction is
necessary in renal disease to prevent drug and
metabolite accumulation. Further, many of these
agents are nephrotoxic themselves, and concerns of
prolonging AKI are legitimate. However, the
combination of very efficient RRTs and concerns
about giving excessive doses has in our opinion,
resulted in an unintended consequence of antibiotic
underdosing in many (most?) patients receiving
CRRT. As mentioned in the quote that leads this
article, it is time for some reflection on this unin-
tended consequence if we are going to achieve any-
thing useful.
Antibiotic Pharmacotherapy in CRRT circa
2014
Sepsis is a common cause of AKI in critically ill
patients, with 70% of those requiring some type of
renal replacement therapy (RRT) (2). Adequate
antibiotic dosing is essential to minimize the mor-
bidity and mortality of sepsis, but is very challeng-
ing due to the complexity associated with
underlying diseases and their unpredictable impact
on pharmacokinetic properties of drugs. Variance in
RRT modalities and regimens and a discrepancy
between prescribed and delivered RRT regimens
can further compound the issue. No prospectively
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validated guidelines exist to aid antibiotic dosing
for these patients. Clinicians frequently consult
renal dosing references or software programs such
as Micromedex for help. However, these recom-
mended doses are often based on in vitro studies,
case reports, or very small clinical pharmacokinetic
trials often using obsolete CRRT technologies or
techniques. Often the recommendations are extrapo-
lated from pharmacokinetic data obtained in non-
critically ill patients or patients with end stage renal
disease (ESRD) receiving other renal replacement
therapies (3). Published clinical pharmacokinetic
experience usually lacks vital information necessary
to apply published results to patient care (4,5).
Given the myriad of potential combinations of
diffusion, convection, flow rates, filters, patient
characteristics, and co-morbidities that are found in
clinical practice and the highly variable pharmacoki-
netic characteristics in critically ill patients, most
published guidelines have limited applicability to
clinical practice. The evidence suggests that despite
the availability of many published CRRT drug dos-
ing guidelines, we rarely meet pharmacodynamic
targets for antibiotics (6–9), and patient mortality
rates remain grim with inadequate antibiotic therapy
as the most important risk factor for death (10).
Because CRRT uses a pump running at a con-
stant setting to generate spent dialysate and ultrafil-
trate, some have taken a more mathematical
approach toward determining appropriate antibiotic
dosing. Various dosing equations for critically ill
patients receiving CRRT have been published.
These also have not been prospectively validated,
but the idea that antibiotic dosing regimens could
be created if you had an understanding of drug
removal by the CRRT system was a logical
approach. To determine the merit of this approach,
we compared the antibiotic doses calculated from
three different published drug dosing equations in
CRRT [Kroh (11), Reetze-Bonorden (12), and
Bugge (13)] to one another and to doses from a
commonly used renal dosing book [Aronoff et al.
(14)] for a hypothetical 70 kg anuric adult receiving
CRRT with the KDIGO recommended effluent rate
of 25 ml/minute (21.4 ml/kg/hour). Necessary
pharmacokinetic data were obtained from published
literature and manufacturer data.
Table 1 illustrates the wide variability found in
calculated antibiotic doses with the 3 equations and
the recommended doses from the Aronoff text. For
example, the calculated doses of piperacillin ranged
5,370–11,181 mg/day, while the Aronoff text sug-
gests a dose of 12,000 mg/day. These published
equation-based techniques make mathematical
sense, in that doses rise as effluent rates rise, and
presumably underwent thorough peer review to
evaluate their suitability. On the basis of their
“logic” and the fact that they have appeared in
print, clinicians could reasonably choose any one of
these as the basis of their antibiotic dosing in their
practices. We are aware that each of these
approaches are used in clinical settings around the
globe, with some clinicians having gone so far as
developing an “app” on their smartphones to do
the calculations for them. In contrast, authors of
the Aronoff text (disclosure: BAM was an author
on Aronoff text) applied pharmacokinetic data from
CRRT trials to develop an antibiotic’s dose which
was determined by consensus with a group of
CRRT experts examining the data.
Despite the “rationality” of any of these
approaches, more recent literature suggests that we
are missing the dosing mark by a wide margin. For
example, in the aforementioned piperacillin example,
the calculated dose range of 5,370–12,000 mg/day
contrasts with the data from Seyler et al. who found
that 16,000 mg/day of piperacillin (in the form of
piperacillin/tazobactam) met defined antibiotic phar-
macodynamic targets in only 71% of patients receiv-
ing CRRT with a mean effluent rate of ~45 ml/kg/
hour (6). Although Seyler et al. used an aggressive
pharmacodynamic target and a higher effluent rate,
the evidence increasingly suggests that nearly every-
thing clinicians think they know about therapeutic
antibiotic dosing in patients receiving CRRT needs
rethinking.
Why Might Antibiotic Underdosing Be
“Overprevalent”?
When we reflect on what we learned in our years
of training as pharmacists, we find that much of
what we had been taught about antibiotic dosing in
this patient population was probably wrong. In the
early years of CRRT, we were taught to use the siev-
ing coefficient of the drug and calculate CRRT clear-
ance. We simply replaced the amount of cleared
drug with an adjusted antibiotic dose, without con-
sideration of the many pharmacokinetic differences
between ESRD patients and critically ill AKI
patients. Pharmacists were trained to aggressively
lower antibiotic doses in patients with kidney disease
to avoid antibiotic toxicity and to reduce drug cost
(15). However, a balance needs to be struck between
concerns of toxicity that limits the dose and the
understanding of altered pharmacokinetics in criti-
cally ill patients that requires larger doses.
Besides the fact that blind reliance on any pub-
lished dosing resource can be problematic, what are
TABLE 1. Comparison of recommended antibiotic dosing by 4 dif-
ferent resources for a hypothetical 70 kg anuric adult receiving
CRRT with the effluent rate of 25 ml/minute (11–14)
Antibiotics
Aronoff
(mg/day)
Kroh
(mg/day)
Reetze-
Bonorden
(mg/day)
Bugge
(mg/day)
Cefepime 4,000 2,150 935 2,363
Daptomycin 280 328 378 242
Linezolid 1,200 797 1,526 770
Meropenem 3,000 1,227 1,899 1,477
Piperacillin 12,000 5,370 11,181 6,882
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some of the things we think we know about antibi-
otic dosing that are also probably wrong?
1. The degree or characteristics of pharmacoki-
netic alteration in critically ill patients with
AKI should not be presumed to be the same as
those with ESRD. For example, patients with
AKI may, for unclear reasons, exhibit rela-
tively higher nonrenal clearance which can sig-
nificantly remove several antibiotics including
imipenem, meropenem, and vancomycin (16–
18), compared with those with ESRD. Thus,
patients with AKI may require a higher antibi-
otic dosage than those with ESRD.
2. The usage of “one-size-fit-all” dosing strategy
(e.g., a fixed dose, regardless of body mass)
carry bias due to lack of integration of the var-
iability in body sizes and body fluid composi-
tions of patients. Patients with AKI often
exhibit a larger drug volume of distribution
due to sepsis, fluid overload, and obesity. We
recently reviewed data on 94 consecutive
patients receiving CRRT in our institution’s
ICUs in 2011. We found that the median [IQR]
patient weight was 101.5 kg [84–134 kg] at
CRRT initiation. It is likely that manufacturer-
recommended antibiotic doses were not derived
from subjects >100 kg. One-size-fit-all or flat
antibiotic dosing may not achieve serum con-
centration goals in these large patients.
Increased body mass index is reported as a sig-
nificant risk factor of antibiotic therapy failure
(19). Thus, it may be prudent to employ
weight-based dosing regimens in cases where a
patient’s body size and fluid composition devi-
ate from the normal ranges.
3. Increasing evidence of an association between
initially low serum antibiotic concentrations/
suboptimal antibiotic therapy and a decrease in
pathogen susceptibility suggest the necessity of
early attainment of pharmacodynamic goals
(20,21). In contrast to our current, relatively
cautious antibiotic dosing practices in patients
with AKI, higher antibiotic dosing may be nec-
essary initially to reduce the incidence of anti-
biotic resistance. Accounting for constant
extracorporeal drug removal via CRRT and
altered pharmacokinetics, very large initial
doses may be needed to maximize therapeutic
efficacy. Utilization of a loading dose may be
beneficial not only in antibiotics with concen-
tration-dependent killing (e.g., aminoglyco-
sides) to achieve a higher initial peak, but also
those with time-dependent killing (e.g., beta-
lactams, vancomycin) to allow target serum
concentration to be reached as early as possi-
ble. Most clinicians never use an antibiotic
loading dose in these patients.
4. “Adequate” concentrations in the serum should
not be interpreted as an equivalent concentra-
tion at the actual sites of infection which
mostly occurs in tissues. Impaired tissue pene-
tration because of altered pathophysiology and
transporter activity in this population may
result in a subtherapeutic infection site concen-
tration despite a “therapeutic” serum concen-
tration (22–24). The same clinicians that
generally recognize the difficulty of getting ade-
quate local antibiotic concentrations in diabetic
foot infections don’t often consider similar
challenges in massively edematous AKI
patients. Until novel methods to measure drug
concentrations at the infection site such as mic-
rodialysis (25) become available, higher antibi-
otic doses may be warranted to ensure
adequate antibiotic therapy.
5. The influence of RRT dose intensity must be
taken into account when designing an antibi-
otic dosing regimen. Over the past decade, the
most common CRRT debate has been about
CRRT dose intensity. The early report from
Ronco suggested that high volume CVVH was
superior to lower doses (26). In contrast, this
study was followed by very large multicenter
trials (27–29) that consistently found that
patient outcomes did not differ between more
aggressive and less aggressive CRRT. The
nephrology and critical care community
appears to have embraced this view, and
guidelines have been published that recom-
mend relatively low intensity CRRT (30).
However, as Kielstein has opined, the study
designs of the trials comparing high and low
intensity CRRT had one common flaw:
patients in both CRRT groups received the
same antibiotic doses (31,32). Consequently,
not only were these studies comparing high
and low CRRT intensity, but they were also
comparing lower antibiotic serum concentra-
tions (high intensity) vs. higher antibiotic
serum concentrations (low intensity). If appro-
priate antibiotic dosing and antibiotic exposure
is important in septic patient outcomes, and
the evidence suggests that it is (10, 33), then it
is quite interesting that patient outcomes with
high intensity CRRT were not inferior to low
intensity CRRT. If one follows this line of
logic, it opens up an entirely new perspective.
Would high CRRT intensity have better
patient outcomes if antibiotic serum concentra-
tions/antibiotic exposure was kept equal
between the groups? More aggressive CRRT
means more rapid antibiotic removal (34), but
because we cannot routinely measure serum
levels of most antibiotics, we generally cannot
discern inadequate antibiotic exposure.
Toward More Appropriate Antibiotic Dosing
When we address this issue in national forums,
we routinely ask the audience the following two
questions:
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1. Of the last 10 CRRT patients you treated, how
many exhibited signs or symptoms of receiving
too much antibiotic?
2. Of the last 10 CRRT patients you treated, how
many died of infection?
Invariably, the answer to question 1 is zero.
Because sepsis is such a prevalent diagnosis in
CRRT patients, the answer to question 2 is gener-
ally two to three deaths. This consistent response
may be related to the high infection-related mortal-
ity rate seen in the ICU. These rates have not
improved much since the advent of CRRT despite
substantial advances in CRRT technologies and
improved understanding of antibiotic pharmacoki-
netics/pharmacodynamics. Reappraisal of the evi-
dence as outlined in this paper challenge commonly
held beliefs regarding antibiotic dosing in CRRT
patients. Our too-careful practice of “starting low
and going slow” with antibiotic dosing to avoid the
risk of antibiotic toxicity may lead to an unintended
consequence that is far more harmful to patients.
We believe that commonly held misconceptions of
antibiotic dosing in CRRT are partially responsible
for an “overprevalence” of antibiotic underdosing
and call for clinicians to reflect on their current
practices to strike a more aggressive antibiotic pre-
scription in the intensive care unit so that we can
achieve something “useful”.
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